Abstract
Background: The Heart Failure (HF) Meta-score may be useful in predicting prognosis in patients with primary prevention cardiac resynchronization defibrillators (CRT-D) considering the competing risk of appropriate defibrillator shock versus mortality. Methods: Data from 648 consecutive patients from two centers were used for the evaluation of the performance of the HF Meta-score. The primary endpoint was mortality and the secondary endpoint was time to first appropriate implantable cardioverter-defibrillator (ICD) shock or death without prior appropriate ICD shock. Fine-Gray model was used for competing risk regression analysis. Results: In the entire cohort, 237 patients died over a median follow-up of 5.2 years. Five-year cumulative incidence of mortality ranged from 12% to 53%, for quintiles 1 through 5 of the HF Meta-score, respectively (log-rank P < 0.001). Compared with the lowest quintile, mortality risk was higher in the highest quintile (HR 6.9; 95%CI 3.7–12.8). The HF Meta-score had excellent calibration, accuracy, and good discrimination in predicting mortality (C-statistic 0.76 at 1-year and 0.71 at 5-year). The risk of death without appropriate ICD shock was higher in risk quintile 5 compared to quintile 1 (sub HR 5.8; 95%CI 3.1–11.0, P < 0.001). Conclusions: Our study demonstrated a good ability of the HF Meta-score to predict survival in HF patients treated with CRT-D as primary prevention. The HF Meta-score proved to be useful in identifying a subgroup with a significantly poor prognosis despite a CRT-D.
Original language | English |
---|---|
Pages (from-to) | 73-79 |
Number of pages | 7 |
Journal | International Journal of Cardiology |
Volume | 330 |
DOIs | |
Publication status | Published - 1 May 2021 |
Bibliographical note
Funding Information:Dr. Theuns has received research grants from Biotronik and Boston Scientific and consulting fees from Boston Scientific. Dr. Schaer is listed on the speaker's bureau for Medtronic. Dr. Sticherling has received speaker fees from Boston Scientific, Biotronik and Microport CRM and consulting fees from Biotronik, Boston Scientific, and Medtronic. Dr. Yap is listed as an ad hoc consultant for Medtronic and Boston Scientific and has been a speaker for Medtronic. The other authors have nothing to disclose.
Publisher Copyright: © 2021 The Authors